{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:30:28Z","timestamp":1793802628152,"version":"4.6.1"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Adults with serious mental illness (SMI), type 2 diabetes, and obesity have elevated cardiovascular risk. Glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101RAs) have established cardiometabolic benefits in the general population, but their effects in SMI are unclear. We evaluated whether GLP\u20101RA use was associated with lower risks of incident myocardial infarction (MI), heart failure (HF), and all\u2010cause death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">This was a retrospective propensity score\u2013matched cohort study of 218\u2009043 adults with SMI, type 2 diabetes, obesity, and active antipsychotic or antidepressant medications in the TriNetX database (73 health care organizations). Outcomes were incident MI, HF, and all\u2010cause death at 1 and 3\u2009years. The primary exposure was GLP\u20101RA use versus nonuse; secondary analyses examined semaglutide or tirzepatide. Exploratory analyses evaluated sex, race, and sodium\u2013glucose cotransporter\u20102 inhibitor and dipeptidyl peptidase\u20104 inhibitor use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      GLP\u20101RA use was associated with lower risks of incident MI, HF, and all\u2010cause death. Risk differences at 1 and 3\u2009years were \u22120.007 and \u22120.010 for MI, \u22120.011 and \u22120.018 for HF, and \u22120.039 and \u22120.065 for death (all\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      &lt;0.001). Semaglutide or tirzepatide use was also associated with lower risks of MI, HF, and death (all\n                      <jats:italic toggle=\"no\">P<\/jats:italic>\n                      &lt;0.001). Findings were directionally consistent after accounting for sodium\u2013glucose cotransporter\u20102 inhibitor and dipeptidyl peptidase\u20104 inhibitor use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">Adults with treated SMI, type 2 diabetes, and obesity using GLP\u20101RAs, particularly semaglutide or tirzepatide, had significantly reduced 1\u2010 and 3\u2010year risks of incident MI, HF, and all\u2010cause death versus nonusers. These pooled associations should be interpreted in the context of SMI's clinical heterogeneity and the limitations of administrative case ascertainment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.126.051982","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T11:28:26Z","timestamp":1792150106000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Glucagon\u2010Like Peptide\u20101 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity"],"prefix":"10.1161","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-7279","authenticated-orcid":false,"given":"Samuel B.","family":"Governor","sequence":"first","affiliation":[{"name":"St. John\u2019s Episcopal Hospital","place":["New York, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"D\u00e1vila\u2010Garc\u00eda","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-9273","authenticated-orcid":false,"given":"Eliut","family":"Rivera\u2010Segarra","sequence":"additional","affiliation":[{"name":"Ponce Health Sciences University","place":["Ponce, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0355-4477","authenticated-orcid":false,"given":"Lindsey M.","family":"Filiatreau","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis","place":["St. Louis, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8995-2131","authenticated-orcid":false,"given":"Nelmit","family":"Tollinchi\u2010Natali","sequence":"additional","affiliation":[{"name":"Ponce Health Sciences University","place":["Ponce, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5396-0955","authenticated-orcid":false,"given":"Ekow","family":"Essien","sequence":"additional","affiliation":[{"name":"Aurora Health Care","place":["Kenosha, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3174-0995","authenticated-orcid":false,"given":"Osamah","family":"Altaee","sequence":"additional","affiliation":[{"name":"University of Texas Health San Antonio","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"Otchere","sequence":"additional","affiliation":[{"name":"University of Texas Health San Antonio","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1872-4141","authenticated-orcid":false,"given":"Leopoldo J.","family":"Cabassa","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8554-0011","authenticated-orcid":false,"given":"Victor G.","family":"D\u00e1vila\u2010Rom\u00e1n","sequence":"additional","affiliation":[{"name":"Washington University in St. Louis","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","volume-title":"Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health","author":"Substance Abuse and Mental Health Services Administration","year":"2023","unstructured":"Substance Abuse and Mental Health Services Administration . Key Substance Use and Mental Health Indicators in the United States: Results from the 2022 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality, SAMHSA; 2023. https:\/\/www.samhsa.gov\/data\/report\/2022\u2010nsduh\u2010annual\u2010national\u2010report"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.2502"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20420"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30132-4"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20069"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.156"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(19)30416-X"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.10.010"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00332-3"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001040"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069568"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2025.116592"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(19)30249-9"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-019-0395-3"},{"key":"e_1_3_2_21_2","volume-title":"Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon\u2010Like Peptide\u20101 Receptor Agonist (GLP\u20101 RA) Medications","author":"FDA","year":"2026","unstructured":"FDA . Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon\u2010Like Peptide\u20101 Receptor Agonist (GLP\u20101 RA) Medications. FDA; 2026."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1200\/CCI.17.00067"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2007.11.008"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-016-0963-x"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195002"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-018-1990-6"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674371506000805"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01036-0"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.73705"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/1753-0407.70082"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02915-1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.14092"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-67701-9"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf150"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2026.2621191"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156208"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbae173"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13522"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1153648"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2022.07.006"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(25)00129-4"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.2332"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.3639"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psyneuen.2025.107415"},{"key":"e_1_3_2_45_2","unstructured":"National Institute of Mental Health (NIMH) . https:\/\/www.nimh.nih.gov\/health\/statistics\/mental\u2010illness#part_2538; and https:\/\/www.nimh.nih.gov\/health\/statistics\/mental\u2010illness"},{"key":"e_1_3_2_46_2","first-page":"99","volume-title":"Mental Health, United States","author":"Kessler RC","year":"1998","unstructured":"Kessler RC. A methodology for estimating the 12\u2010month prevalence of serious mental illness. In: Mandersheid RW, Henderson MJ, eds, Mental Health, United States. Washington, DC: U.S. Government Print Office; 1998:99\u2013109."},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.2.184"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.92.1.92"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.126.051982","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:19:10Z","timestamp":1793801950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.126.051982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,20]]},"references-count":47,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,10,20]]}},"alternative-id":["10.1161\/JAHA.126.051982"],"URL":"https:\/\/doi.org\/10.1161\/jaha.126.051982","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,20]]},"assertion":[{"value":"2026-04-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e051982"}}